COVID-19 Publications

Kinetics and seroprevalence of SARS-CoV-2 antibodies in children

Tags: , , | November 24th, 2020

Authors: Cathal Roarty, Claire Tonry, Lisa McFetridge, Hannah Mitcheòò, Chris Watson, Thomas Waterfeild, on behalf of the Covid Warriors research team

Published in: The Lancet Infectious Diseases

Abstract: To the best of our knowledge, no longitudinal study has reported the kinetics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in children. Here we report the results of the second round of antibody testing in children from a prospective multicentre cohort study in the UK. The protocol and initial results are available elsewhere.

Recruitment took place between April 16, and July 3, 2020, at five UK sites (Belfast, Cardiff, Glasgow, London, and Manchester) and included healthy children aged 2–15 years. Follow-up visits at all five UK sites took place between June 26, and Aug 15, 2020.

Of the 992 participants in the first round, 849 (86%) returned. Seroprevalence was measured with the Elecsys Anti-SARS-CoV-2 Total Antibody assay (Roche, Basel, Switzerland) and the LIAISON SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Saluggia, Italy). The median time between initial and follow-up visits was 62 days (IQR 52–70; range 43–81). 65 (7·66%, 95% CI 6·05–9·64) of 849 tests were reactive based on the manufacturers’ suggested cutoffs. This proportion was not substantially different to the seroprevalence (6·9% 95% CI 5·4 to 8·6; 68 of 992) reported during recruitment. The median age of participants with reactive antibody tests during the second round was 10 years (IQR 7–14; range 3–16). As with the baseline results, there was variation in seroprevalence between sites.
Read full article here.

We would like to update you on our recent activities